Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Jul;88(1):14-6.
doi: 10.1038/ki.2015.143.

Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease?

Shigeo Horie  1
Affiliations
Free article
Comment

Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease?

Shigeo Horie. Kidney Int. 2015 Jul.
Free article

Abstract

The vasopressin inhibitor tolvaptan is clinically effective in slowing growth of renal cysts and reduction in estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD), but these effects are mitigated by the associated polyuria. Changes of total kidney volume, eGFR, and symptoms will guide physicians and patients in tolvaptan treatment. Guidance about when to initiate treatment in the course of ADPKD may be forthcoming. Ongoing long-term observations will inform future recommendations about tolvaptan use in ADPKD.

PubMed Disclaimer

Comment on

References

    1. J Am Soc Nephrol. 1995 Jun;5(12 ):2032-6 - PubMed
    1. N Engl J Med. 2012 Dec 20;367(25):2407-18 - PubMed
    1. Clin J Am Soc Nephrol. 2010 Aug;5(8):1471-9 - PubMed
    1. Clin Exp Nephrol. 2015 Oct;19(5):867-77 - PubMed
    1. Ann Intern Med. 2013 Sep 17;159(6):382-9 - PubMed

MeSH terms

LinkOut - more resources